Home » Stocks » AMYT

Amryt Pharma PLC (AMYT)

Stock Price: $12.98 USD -0.02 (-0.15%)
Updated November 24, 12:01 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 2.11B
Revenue (ttm) 180.38M
Net Income (ttm) -89.79M
Shares Out 162.80M
EPS (ttm) -0.55
PE Ratio n/a
Forward PE 67.57
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $12.98
Previous Close $13.00
Change ($) -0.02
Change (%) -0.15%
Day's Open 13.00
Day's Range 12.88 - 13.40
Day's Volume 6,792
52-Week Range 10.06 - 14.95

More Stats

Market Cap 2.11B
Enterprise Value 2.22B
Earnings Date (est) Apr 21, 2021
Ex-Dividend Date n/a
Shares Outstanding 162.80M
Float n/a
EPS (basic) n/a
EPS (diluted) -0.55
FCF / Share n/a
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 8,500
Short Ratio 0.64
Short % of Float n/a
Beta n/a
PE Ratio n/a
Forward PE 67.57
P/FCF Ratio n/a
PS Ratio 11.72
PB Ratio 6.05
Revenue 180.38M
Operating Income n/a
Net Income -89.79M
Free Cash Flow n/a
Net Cash -110.44M
Net Cash / Share -0.68
Gross Margin 14.69%
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA n/a
ROE n/a
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(202.47% upside)
Current: $12.98
Target: 39.26
*Average 12-month price target from 3 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth240.01%-
Gross Profit16.1210.83
Operating Income-53.75-18.04
Net Income-65.54-30.49
Earnings Per Share-4.30-3.35
Operating Cash Flow-37.50-15.45
Capital Expenditures-0.65-0.24
Free Cash Flow-38.15-15.69
Cash & Equivalents67.2311.23
Total Debt17819.01
Net Cash / Debt-111-7.79
Book Value129-3.70
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amryt Pharma PLC
Country Ireland
Employees 169
CEO Joseph Wiley

Stock Information

Ticker Symbol AMYT
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: AMYT


Amryt Pharma plc, a biopharmaceutical company, develops and commercializes novel therapeutics to treat patients suffering from serious and life-threatening rare diseases. The company's commercial products include Myalept/Myalepta, used as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy; and Lojuxta/Juxtapid, a prescription medicine used along with diet and other lipid-lowering treatments, including low-density lipoprotein (LDL) apheresis in adults with homozygous familial hypercholesterolaemia. Its development candidates comprise FILSUVEZ, a potential treatment for the cutaneous manifestations of EB, a rare and distressing genetic skin disorder affecting young children and adults; and AP103, a pre-clinical gene-therapy platform technology that offers a treatment for patients with recessive dystrophic epidermolysis bullosa. The company sells its products in the Americas, Europe, and the Middle East. Amryt Pharma plc was founded in 2015 and is based in London, the United Kingdom.